▟ Vinebot intrinsic value, daily

← back

TMO Thermo Fisher Scientific

pharma · valued with opus medium conviction · deep-dived 2026-10-28

HOLD
Intrinsic value$336.13
Price (at call)$693.02
Margin of safety -51.5%
vs market (rating basis) -13.0%

High-quality biopharma toll road, but the price assumes growth and returns that organic reinvestment hasn't delivered.

The story

Thermo Fisher is the scaled toll-collector on life-science R&D and biopharma manufacturing: instruments, consumables, CDMO and CRO services, with about 80% recurring revenue and unmatched channel breadth. After the post-COVID normalization (revenue flat at about $43-45B from 2022 to 2024), organic growth has resumed in the low-to-mid single digits, and TTM revenue of $46.3B is up roughly 4%. Bolt-ons (Olink, Solventum filtration, Clario) add growth but also capital. It is a mature franchise with a durable moat, and value hinges on organic reinvestment efficiency rather than deal-driven top-line growth.

I raised Y1 growth slightly (5% to 5.5%) because TTM growth has re-accelerated and recent deals will add to it. I nudged the target margin from 23.5% to 24.5% because reported margins carry about 5 points of acquisition amortization that runs off over time, while adjusted margins of about 23% already show that level of underlying profitability (both moves are under 20% relative). Sales-to-capital stays at 1.6 for incremental organic capital; the reported 0.5 reflects legacy goodwill, not marginal economics.

Value drivers

Revenue growth (Y1)5.5%
Terminal growth3.5%
Forecast horizon12y
Target operating margin24.5%
Years to target margin5
Sales-to-capital1.60
Beta0.95
Failure probability1.0%
Cost of capital (WACC)9.0%
Terminal WACC9.2%

Valuation bridge

PV of explicit FCFF83.25B
PV of terminal value71.95B
Equity value124.28B
÷ shares → per share$336.13

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 48.88B 5.5% 20.6% 9.32B 1.59B 7.73B 7.10B
2 51.48B 5.3% 21.6% 10.28B 1.62B 8.66B 7.29B
3 54.13B 5.1% 22.6% 11.30B 1.65B 9.64B 7.46B
4 56.81B 5.0% 23.5% 12.37B 1.68B 10.69B 7.59B
5 59.52B 4.8% 24.5% 13.49B 1.69B 11.80B 7.68B
6 62.25B 4.6% 24.5% 14.11B 1.71B 12.40B 7.41B
7 65.00B 4.4% 24.5% 14.73B 1.72B 13.02B 7.14B
8 67.75B 4.2% 24.5% 15.36B 1.72B 13.64B 6.87B
9 70.49B 4.0% 24.5% 15.98B 1.71B 14.26B 6.59B
10 73.21B 3.9% 24.5% 16.59B 1.70B 14.89B 6.32B
11 75.91B 3.7% 24.5% 17.21B 1.68B 15.52B 6.04B
12 78.56B 3.5% 24.5% 17.81B 1.66B 16.15B 5.77B

Key risks

  • NIH/academic funding cuts and biotech funding drought depress instrument and consumables demand
  • Serial M&A at high multiples destroys value and keeps reinvestment efficiency low
  • China weakness, tariffs, and pharma pricing reform (MFN) pressure biopharma capex and CDMO volumes

Catalysts

  • Bioproduction and pharma-services volume recovery with onshoring-driven US manufacturing build-outs
  • Margin expansion via PPI cost programs and amortization roll-off lifting GAAP margins toward adjusted levels

History

DatePriceIntrinsicMoSRating
2026-10-28$693.02 $336.13 -51.5% HOLD
2026-09-24$665.30 $306.40 -53.9% HOLD
2026-08-21$627.55 $197.86 -68.5% SELL
2026-07-20$532.48 $221.61 -58.4% HOLD
2026-06-23$469.35 $230.24 -50.9% HOLD